Differential regulation of prohormone convertase 1/3, prohormone convertase 2 and phosphorylated cyclic-AMP-response element binding protein by short-term and long-term morphine treatment: implications for understanding the "switch" to opiate addiction.
Drug addiction is a state of altered brain reward and self-regulation mediated by both neurotransmitter and hormonal systems. Although an organism's internal system attempts to maintain homeostasis when challenged by exogenous opiates and other drugs of abuse, it eventually fails, resulting in the transition from drug use to drug abuse. We propose that the attempted maintenance of hormonal homeostasis is achieved, in part, through alterations in levels of processing enzymes that control the ratio of active hormone to pro-hormone. Two pro-hormone convertases, PC1/3 and PC2 are believed to be responsible for the activation of many neurohormones and expression of these enzymes is dependent on the presence of a cyclic-AMP response element (CRE) in their promoters. Therefore, we studied the effects of short-term (24-h) and long-term (7-day) morphine treatment on the expression of hypothalamic PC1/3 and PC2 and levels of phosphorylated cyclic-AMP-response element binding protein (P-CREB). While short-term morphine exposure down-regulated, long-term morphine exposure up-regulated P-CREB, PC1/3 and PC2 protein levels in the rat hypothalamus as determined by Western blot analysis. Quantitative immunofluorescence studies confirmed these regulatory actions of morphine in the paraventricular and dorsomedial nucleus of the hypothalamus. Specific radioimmunoassays demonstrated that the increase in PC1/3 and PC2 levels following long-term morphine led to increased TRH biosynthesis as evidence by increased TRH/5.4 kDa C-terminal proTRH-derived peptide ratios in the median eminence. Promoter activity experiments in rat somatomammotrope GH3 cells containing the mu-opioid receptor demonstrated that the CRE(s) in the promoter of PC1/3 and PC2 is required for morphine-induced regulation of PC1/3 and PC2. Our data suggest that the regulation of the prohormone processing system by morphine may lead to alterations in the levels of multiple bioactive hormones and may be a compensatory mechanism whereby the organism tries to restore its homeostatic hormonal milieu. The down-regulation of PC1/3, PC2 and P-CREB by short-term morphine and up-regulation by long-term morphine treatment may be a signal mediating the switch from drug use to drug abuse.
Espinosa
V Paez
VP
Division of Endocrinology, Department of Medicine, The Charles Drew University of Medicine & Sciences-UCLA School of Medicine, 1731 East 120th Street, Los Angeles, CA 90059, USA.
Liu
Y
Y
Ferrini
M
M
Anghel
A
A
Nie
Y
Y
Tripathi
P V
PV
Porche
R
R
Jansen
E
E
Stuart
R C
RC
Nillni
E A
EA
Lutfy
K
K
Friedman
T C
TC
D000818:Animals; D001522:Behavior, Animal; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D002461:Cell Line, Transformed; D017362:Cyclic AMP Response Element-Binding Protein / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects*; D008297:Male; D009020:Morphine / Q000009:adverse effects / Q000494:pharmacology*; D009294:Narcotics / Q000009:adverse effects / Q000494:pharmacology*; D010147:Pain Measurement; D045664:Proprotein Convertase 1 / Q000235:genetics / Q000378:metabolism*; D045706:Proprotein Convertase 2 / Q000235:genetics / Q000378:metabolism*; D011863:Radioimmunoassay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D011930:Reaction Time / Q000187:drug effects; D013375:Substance Withdrawal Syndrome / Q000188:drug therapy / Q000503:physiopathology; D013973:Thyrotropin-Releasing Hormone / Q000378:metabolism; D013997:Time Factors; D014162:Transfection
D017362:Cyclic AMP Response Element-Binding Protein; D009294:Narcotics; D013973:Thyrotropin-Releasing Hormone; D009020:Morphine; D045664:Proprotein Convertase 1; D045706:Proprotein Convertase 2
J Biol Chem. 1995 Jun 23;270(25):15391-7
7797529
Endocrinology. 1991 Dec;129(6):3053-63
1954888
Endocrinology. 2004 Feb;145(2):519-28
14576186
Am J Addict. 2001 Summer;10(3):201-17
11579619
Neuroreport. 1996 Sep 2;7(13):2196-200
8930988
J Neurochem. 1995 Nov;65(5):2318-26
7595521
Neuropharmacology. 1980 Jan;19(1):117-20
7360325
J Neurochem. 2002 Mar;80(5):874-84
11948251
J Neurochem. 1992 Mar;58(3):1168-71
1531356
J Neurosci. 1997 Oct 15;17(20):7890-901
9315909
J Neurosci. 2006 Oct 11;26(41):10372-5
17035520
Proc Natl Acad Sci U S A. 1997 Jun 24;94(13):6646-51
9192619
J Pharmacol Exp Ther. 1996 Oct;279(1):351-8
8859013
Mol Pharmacol. 1995 May;47(5):1041-9
7746271
Brain Res. 1991 May 10;548(1-2):100-10
1651140
Neuron. 1996 Oct;17(4):567-70
8893013
J Neurosci. 2002 May 1;22(9):3663-72
11978842
Brain Res. 1990 Jun 11;519(1-2):102-11
2144463
Methods Enzymol. 1994;244:175-88
7845206
J Neurochem. 1995 Dec;65(6):2462-72
7595540
Annu Rev Med. 2004;55:113-32
14746512
J Mol Med (Berl). 1998 Feb;76(2):104-10
9500675
Neuropeptides. 1993 Aug;25(2):91-4
8413862
Science. 1996 Aug 2;273(5275):657-9
8662559
J Pharmacol Exp Ther. 1988 Sep;246(3):1033-9
2843624
Biochem J. 1997 Nov 15;328 ( Pt 1):69-74
9359835
Mol Endocrinol. 1997 Sep;11(10):1425-34
9280058
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10299-304
12136131
Endocr Rev. 1999 Oct;20(5):599-648
10529897
Mol Cell Endocrinol. 1999 Dec 20;158(1-2):143-52
10630414
Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10293-8
12145326
Regul Pept. 2001 Dec 15;102(2-3):135-45
11730986
Science. 1997 Oct 3;278(5335):58-63
9311927
J Biol Chem. 1997 Jan 24;272(4):2500-8
8999965
Proc Natl Acad Sci U S A. 2006 May 16;103(20):7883-8
16682632
DNA Cell Biol. 1990 Jul-Aug;9(6):415-24
2169760
Nature. 1996 Oct 31;383(6603):819-23
8893006
Science. 1997 Jun 27;276(5321):2050-4
9197270
J Neurochem. 2000 Oct;75(4):1763-70
10987860
Mol Endocrinol. 1991 Jan;5(1):111-22
2017186
N Engl J Med. 1998 Jan 15;338(3):171-9
9428819
Annu Rev Cell Dev Biol. 1995;11:355-77
8689562
Science. 1997 Oct 3;278(5335):52-8
9311926
Life Sci. 2003 Jun 27;73(6):759-68
12801597
Mol Endocrinol. 1992 Mar;6(3):485-97
1316544
Mol Cell Endocrinol. 1996 Jan 15;116(1):89-96
8822269
Science. 1997 Oct 3;278(5335):45-7
9311924
J Neurosci. 1998 Dec 1;18(23):9989-95
9822754